Subsequently, ivosidenib (mIDH1 inhibitor) and enasidenib (mIDH2 inhibitor) were developed and tested in patients with hematologic malignancies with IDH mutations, such as acute myeloid leukemia (AML). This evidence concerns the gene IDH2 and acute myeloid leukemia.